Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
June 1, 2009
- Otsuka HD: Sales of Healthcare Products Up to ¥676.7 Bil.
June 1, 2009
- GENERICS NEWS IN BRIEF
June 1, 2009
- Zeria: Mid-Term Sales Target Down to ¥73 Bil.
June 1, 2009
- Quintiles Named Most Favored CRO in 2 Independent Surveys
June 1, 2009
- ASKA: Profits Plummet with Flat Sales
June 1, 2009
- 60% of Patients Prefer In-House Prescriptions at Sanjou Hospital
June 1, 2009
- Seikagaku: Sales of Artz Up in Japan, China
June 1, 2009
- Cumulative Total of 787 Deaths Reported in Iressa-Treated Patients
June 1, 2009
- Nippon Chemiphar: Profits Sinks as Sales of Generics Increase
June 1, 2009
- Draft Report on Proper Preparation, Use of Fertilized Human Embryos Approved
June 1, 2009
- Rush of Orders on Gargles, Masks
June 1, 2009
- Wakamoto: Profits Down due to Poor Stock Management
June 1, 2009
- Champix Cuts Lifetime Medical Spending by ¥30,000
June 1, 2009
- Average Operating Profit Rate Down to 0.38% for Top-Four Wholesalers
June 1, 2009
- Teijin: Pharma & HHC Business Remains Bullish
June 1, 2009
- JSMI Announces Vision for Activation of OTC Drug Industry
June 1, 2009
- Suzuken: Sharp Fall in Profits Despite 3.4% Increase in Sales
June 1, 2009
- Meiji HD: Generics Bolster Pharma Business
June 1, 2009
- Reform of Profit Structure "Task of Pressing Urgency": Mr Kumakura
June 1, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…